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Abstract Prophylactic interventions have lead to the
reduction of the mother-to-child transmission (MTCT) of
human immunodeficiency virus type 1 (HIV-1) to less than
2% in industrialized countries. The aim of this study was to
evaluate the changes over time in vertical transmission
according to the standard care of prophylaxis in the practice
of a single large reference center and to identify the risk
factors for failure. The rate of MTCT decreased progres-
sively from 10% in 1986–1993 to 4.7% in 1999–2002,
reflecting the progressive implementation of newly avail-
able means of prevention. During the last period evaluated
(1999–2002), where highly active antiretroviral therapy
(HAART) prophylaxis was the standard of care, 17% of
women had a viral load between 400 and 20,000 copies/ml
around delivery and 5% had a viral load above 20,000
copies/ml. High viral load and low CD4 lymphocyte count
were strongly associated with vertical transmission. The
rate of MTCT in women who received HAART for more
than one month during pregnancy was 1.7%, compared to
13.3% in women treated with HAART for less than
one month. The risk of vertical transmission in the absence
of therapy was four times higher than before the era of
antiretroviral therapy (ART; p=0.05). In conclusion, since
the prevention of MTCT of HIV with HAART is the
standard of care, a short duration or absence of ART during
pregnancy linked to late or absent prenatal care is
associated with a high risk of transmission. The early
detection of HIV-1 infection in pregnant women, and close
follow up and support during pregnancy are crucial to the
success of the prevention of transmission.
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Without any prophylaxis, the mother-to-child transmission
(MTCT) rate of the human immunodeficiency virus type 1
(HIV-1) varies from 12 to 20% in industrialized countries,
but reaches 35 to 40% in Africa, where breast-feeding is the
norm [10, 17].
Formula feeding was the first measure proposed to
reduce the exposure of the newborn to the virus. In 1994,
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the efficacy of zidovudine (ZDV) given to the mother
during pregnancy and delivery and to the newborn has been
demonstrated to reduce MTCT [2]. In 1998, elective
cesarean section has been recommended as an additional
effective measure [6, 10, 11, 13]. Since 1996, the
administration of highly active antiretroviral therapy
(HAART) to HIV-infected pregnant women has been
progressively generalized in industrialized countries. The
combination of these preventive measures have lead to the
reduction of MTCT to less than 2% [1, 12].
Between 1986 and 2002, 361 singletons babies born to
HIV-infected mothers were followed up from birth in our
center. During this period of time, the measures to prevent
vertical transmission were made a part of standard care at
the time they were implemented in most industrialized
countries. This retrospective cohort study was conducted to
evaluate the changes over time in the vertical transmission
rates.
Methods
This is a retrospective cohort study on vertical transmission
in infants born to HIV-1-infected mothers over the period
1986–2002.
Study population
All 361 singleton babies born alive between 1986 and 2002
from an HIV-1-infected mother and followed up since birth
in our center were included in this study; eight twin pairs
were excluded.
As the prophylactic measures used changed over time,
we divided the whole group into three birth cohorts:
– Births between 1986 and 1993 (cohort 86–93): preven-
tive measures included obstetrical interventions to
shorten the duration of membrane rupture and the
exposure of the newborn to the mother’s blood and
vaginal secretions, together with the avoidance of
breast-feeding.
– Births between 1994 and 1998 (cohort 94–98): in
addition to the above, ZDV was given to the mother
during the last trimester of pregnancy, intravenously
during delivery and orally to the infant over the first
6 weeks of life. During a short period of time (October
1997 to 1998), the combination of ZDV and lamivu-
dine was used in newborns.
– Births between 1999 and 2002 (cohort 99–02): the
recommendation to perform an elective cesarean
section at 38 weeks of gestation was introduced for
all pregnancies and HAART was given during (at least)
the last trimester of pregnancy.
Data collection
The following data were abstracted from the mothers’
medical records: ethnicity, parity, maternal age at delivery,
time of maternal HIV diagnosis (before pregnancy, during
pregnancy, or at delivery), type, and duration of maternal
antiretroviral therapy (ART) regimen, viral load, CD4
lymphocyte count and maternal CDC stage at delivery.
The obstetrical data included: date, mode of delivery,
gestational age, episiotomy, and time between rupture of
the amniotic membranes and delivery. The data from the
newborns included: birth weight and diagnosis of HIV
infection. Before 1994, viral culture and the persistence of
HIV-1-specific antibodies after the age of 18 months were
used to establish HIV infection in children, but since 1994,
the diagnosis of HIV infection is based on the detection of
proviral HIV DNA and/or by the determination of plasma
HIV RNA viral load in two separate blood samples
(Amplicor method).
Outcome
The main outcome was the MTCT of HIV. Secondary
outcomes were preterm birth (<37 weeks of gestation) and
low birth weight (<2,500 g).
Statistical analysis
We computed the risk of vertical transmission of HIV and
the risk of preterm birth according to maternal character-
istics, preventive measures used, and period. We used
logistic regression modeling to estimate the adjusted odds
ratios (ORs) for the associations of different interventions
implemented during pregnancy with the outcomes. Among
361 pregnancies, 34 were second and four were third
consecutive pregnancies to the same mother in the cohort;
they were considered as independent events. As data are
often missing for the first period (1986–1993), some
analyses only included the last two periods.
Statistical significance was assigned by a two-sided
alpha level of 0.05. All p-values are two-tailed. Statistical
analysis was performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL).
Results
The distribution of the maternal characteristics of the 361
infants included in the study, divided into the time cohorts,
is shown in Table 1. Most of the mothers were of sub-
Saharan African origin and had acquired HIV heterosexu-
ally. Maternal age and the proportion of non-European
mothers increased over time.
80 Eur J Pediatr (2009) 168:79–85
Risk of vertical transmission
Table 2 describes the outcomes for each birth cohort
according to the preventive measures other than avoiding
breast-feeding. None of the mothers had ART given during
pregnancy between 86–93, whereas, respectively, 86% and
95% of the 94–98 and 99–02 cohorts received antiretroviral
prophylaxis. Over the whole period, vertical transmission
occurred in 26 of the 361 infants. There was a progressive
decline, although not significant, in the risk of vertical
transmission between cohort 86–93 and cohort 99–02. A
subgroup analysis of the women who did not receive ART
during pregnancy showed a strong linear increase over time
in the risk of vertical transmission: the risk was 10/100
(10.0%; 95%CI: 4.9%–17.6%) in the 86–93 cohort, 3/16
(18.8%; 95%CI: 4.0%–45.7%) in the 94–98 cohort, and
Table 2 Preventive measures and outcomes distribution according to birth cohort
Cohort 86–93 Cohort 94–98 Cohort 99–02 p-value
n=100 n=111 n=150
Type of ART regimen during pregnancy
No ART 100 (100%) 16 (14.4%) 8 (5.3%)
Mono or dual therapy 0 (0%) 94 (84.7%) 11 (7.3%)
Triple or quadruple therapy 0 (0%) 1 (0.9%) 131 (87.3%) <0.001§
More than one month of ART during pregnancy 0 (0%) 58 (59.8%) 122 (81.3%) <0.001§
Elective cesarian section 8 (8.7%) 37 (33.9%) 89 (59.7%) <0.001
Less than 4 h between rupture of the amniotic membranes and childbirth 19 (57.6%) 75 (75.8%) 130 (87.8%) <0.001
Episiotomy 19 (27.9%) 11 (10.1%) 8 (5.4%) <0.001
Vertical transmission 10 (10.0%) 9 (8.1%) 7 (4.7%) 0.10*
Gestational age at birth <37 weeks 12 (12.0%) 13 (11.7%) 20 (13.3%) 0.91£
Birth weight <2,500 g 13 (13.5%) 14 (12.6%) 20 (13.3%) 0.98£
*Test for linear trend
£ Pearson chi-square
§ p-value for the comparison between cohort 94–98 and cohort 99–02
Table 1 Maternal characteristics according to birth cohort
Cohort 86–93 Cohort 94–98 Cohort 99–02
n=100 n=111 n=150
n (%), mean (standard deviation) p-value
Maternal age (years) 27.6 (4.7) 29.5 (4.4) 30.7 (5.5) <0.001
Parity
One 16 (21.3%) 30 (28.0%) 50 (33.3%)
Two to three 41 (54.7%) 50 (46.7%) 82 (54.7%)
Four or more 18 (24.0%) 27 (25.2%) 18 (12.0%) 0.03
Non-European mother 61 (69.3%) 86 (79.6%) 124 (84.9%) 0.02
Time of maternal HIV diagnosis
Before pregnancy 52 (50.5%) 88 (58.7%)
During pregnancy 48 (46.6%) 57 (38.0%)
During delivery NA 3 (2.9%) 5 (3.3%) 0.38*
Maternal CDC stage at delivery
A 90 (88.2%) 98 (66.7%)
B 6 (5.9%) 39 (26.5%)
C NA 6 (5.9%) 10 (6.8%) <0.001
Viral load at delivery (copies/ml)
≤400 114 (78.1%)
401–20,000 25 (17.1%)
>20,000 NA NA 7 (4.8%) –
CD4 at delivery <100 cells/ml NA 5 (5.6%) 1 (0.7%) 0.03*
CD4 at delivery (cells/ml)£ NA 450 (6–1,515) 412 (90–1,656) 0.31
*Exact test
£Median (min–max) and Mann-Whitney test
NA=not available
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reached 3/8 (37.5%; 95%CI: 8.5%–75.5%) in the 99–02
cohort. Between 1999 and 2002, seven of the 150 infants
were infected (4.7%; 95%CI: 1.9%–9.4%): three were born
to mothers who did not receive ART prophylaxis because
HIV diagnosis was made at delivery, two were born to
mothers who received HAART for less than one month,
and two to mothers who received HAART for more than
one month during pregnancy.
High viral load and low CD4 lymphocyte count were
strongly associated with vertical transmission. In the last
cohort, among the seven mothers with a viral load >20,000
copies/ml around the time of delivery, two infants were
infected, compared with four infants (3%) born to 139
mothers who had a viral load <20,000 copies/ml (risk ratio
[RR]: 9.9; 95%CI: 2.2–45.3; p=0.027). In the period 94–02,
among six mothers who had CD4 lymphocyte count <100
cells/ml, three transmissions occurred, compared with 11/
229 (5%) among the mothers with a higher level of CD4
(RR: 10.4; 95%CI: 3.9–27.9; p=0.003).
Table 3 shows the associations between the type and
duration of prophylaxis during pregnancy, obstetrical
characteristics, and the risk of MTCT. The lowest risk of
vertical transmission (1.7%; 95%CI: 0.2%–6.1%) was
observed for mothers who received HAART for >1 month
during pregnancy. Among the women who received
prophylaxis, the risk of vertical transmission was greater
when HAART was administered for <1 month as compared
to >1 month (adjusted OR=6.7). Women who received a
mono or a dual therapy for >1 month during pregnancy had
a higher risk of transmission compared with those who
received HAART for >1 month (adjusted OR=2.5), but this
difference was not statistically significant. Performing an
episiotomy was not a risk factor of vertical transmission
after adjustment for treatment.
Table 4 shows the characteristics of mothers and
pregnancies where vertical transmission occurred despite
ART prophylaxis administered for >1 month during
pregnancy. In the last three infants, the transmission
occurred most probably during delivery, since the first
polymerase chain reaction (PCR) obtained at birth was
negative. The first mother was severely immunodepressed
and reported a poor adherence to treatment and the second
received ZDV only during the third trimester. The last two
mothers had detectable viral load on delivery.
Risk of preterm delivery
Table 5 shows the association between the type and
duration of ART prophylaxis during pregnancy and preterm
delivery. Since the introduction of ART, mothers remaining
untreated during pregnancy were more likely to be
diagnosed late or to deliver prematurely. Therefore, the
reference group we used was the group of women treated
with mono or dual therapy.
The risk of preterm delivery (<37 weeks) was higher for
women who received HAART and for untreated women
compared to women who received mono or dual therapy.
Interestingly, this risk was higher in women treated with
HAART for <1 month compared to women treated with
HAART for a longer duration. Among the women treated
for >1 month, HAART was associated with low birth
weight (<2,500 g) (adjusted OR: 1.4; 95%CI: 0.4–4.6 for
Table 3 Crude and adjusted odds ratio (OR) for the risk of vertical transmission according to the type and duration of antiretroviral therapy
(ART) during pregnancy and according to obstetrical characteristics (1994–2002)
Infected infants, n (%) Crude OR (95%CI) p-value* Adjusted£ OR (95%CI) p-value*
Type of ART
None 6/24 (25.0%) 19.0 (3.6–101.5) 25.9 (3.5–190.8)
Mono or dual therapy ≤1 month 3/28 (10.7%) 6.8 (1.1–43.1) 6.7 (0.8–58.4)
Mono or dual therapy >1 month 2/64 (3.1%) 1.8 (0.3–13.4) 2.5 (0.3–20.0)
Tri or quadri-therapy ≤1 month 2/15 (13.3%) 8.8 (1.1–67.6) 6.7 (0.7–59.7)
Tri or quadri-therapy >1 month 2/116 (1.7%) 1.0 0.004 1.0 0.02
Mode of delivery
Vaginal delivery with episiotomy 2/19 (10.5%) 2.0 (0.4–10.4) 0.8 (0.1–11.0)
Vaginal delivery without episiotomy 4/78 (5.1%) 0.9 (0.3–3.2) 0.4 (0.1–2.4)
Emergency cesarean section 3/33 (9.1%) 1.7 (0.4–7.0) 1.7 (0.3–9.1)
Elective cesarean section 7/126 (5.6%) 1.0 0.73 1.0 0.57
Duration between rupture of the amniotic membranes and childbirth
<4 12/205 (5.9%) 1.0 1.0
≥4 4/42 (9.5%) 1.7 (0.5–5.5) 0.38 1.4£ (0.3–6.7) 0.65
OR=odds ratio; CI=confidence interval
*Wald test
£ Adjusted for age, parity, ethnicity, and other variables presented in the table (duration between rupture of the amniotic membranes and childbirth
was not entered in models simultaneously with the mode of delivery because of colinearity)
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HAART compared with mono or dual therapy). These
associations, however, were not statistically significant.
Discussion
Since the introduction of antiretroviral prophylaxis during
pregnancy, the rate of MTCT of HIV has dramatically
decreased in developed countries. In 1994, the PACTG076
study showed that ZDV given to the mother during
pregnancy, delivery, and to the newborn could reduce the
risk of transmission from 25% to 8% [2]. By 1996,
combination ART progressively became the standard of
care for the prevention of MTCT. In recent studies, the
transmission was shown to be reduced to <2% in mothers
treated with HAART [3, 5]. Our study aimed primarily at
reviewing the impact of prophylactic measures on vertical
transmission in a single reference center cohort of infants
born to HIV-1-infected mothers between 1986 and 2002.
The decrease in the vertical transmission rate from 10%
in 1986–1993 to 4.7% in 1999–2002 reflects the progres-
sive implementation of newly available means of preven-
tion. Whilst the transmission rate is 4.7% globally for the
cohort in the era of HAART, it is lower than 2% in women
who received HAART for more than one month during
pregnancy.
The timing of the diagnosis has an obvious impact on the
feasibility of implementing prophylactic measures to reduce
MTCT. During the period 94–02, 43% of the women were
diagnosed with HIV infection during pregnancy or at
delivery, and 24/261 (9%) had no antenatal ART prophy-
laxis: the MTCT rate in this small group of patients was
25%. The risk of vertical transmission in untreated women
in the era of HAART was four times higher than in the
group of mothers followed before 1994 (p=0.05). This
suggests that factors such as late diagnosis during pregnan-
cy, poor antenatal care, insufficient implementation of
preventive interventions associated or not with social
Table 5 Risk of preterm birth (<37 weeks) according to the administration of ART during pregnancy (1986–2002)
n (%) Crude OR (95%CI) p-value* Adjusted OR§(95%CI) p-value*
Type of treatment during pregnancy
None 15 (12.1%) 1.3 (0.6–3.0) 1.4 (0.5–4.2)
Mono or dual therapy 10 (9.5%) 1.0 1.0
Tri or quadri-therapy 20 (15.2%) 1.7 (0.8–3.8) 0.43 2.5 (1.0–6.5) 0.15
Duration of ART during pregnancy
None 15 (12.1%) 1.8 (0.4–8.3) 2.2 (0.3–19.1)
Mono or dual therapy ≤1 month 2 (7.1%) 1.0 1.0
Mono or dual therapy >1 month 6 (9.4%) 1.4 (0.3–7.1) 1.4 (0.1–13.4)
Tri or quadri-therapy ≤1 month 6 (40.0%) 8.7 (1.5–50.9) 10.1 (1.0–103.2)
Tri or quadri-therapy >1 month 13 (11.2%) 1.6 (0.4–7.7) 0.04 3.1 (0.4–25.9) 0.08
OR=odds ratio; CI=confidence interval
*Wald test
§Adjusted for age, parity, and ethnicity
Table 4 Characteristics of mothers and pregnancies where vertical transmission occurred despite ART prophylaxis being administered for longer






Ethnicity Parity BF HIV
diagnosis










1994 29 A 1 no before P C3 NA 18 ZDV 2nd and
3rd trimester
– poor no ECs NA 36




good no VD neg 41





good no ECs neg 38




poor no ECs neg 38
A=African; E=European; P=pregnancy; VL=viral load; GA=gestational age; BF=breast-feeding; ECs=elective cesarean section; VD=vaginal
delivery; NA=not available
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precarity play a significant role in vertical transmission. The
duration of prophylaxis appeared to play a crucial role in its
effectiveness. Among the mothers treated with HAART for
<1 month, 13.3% transmitted HIV to their newborn
compared with 1.7% in mothers treated for >1 month.
Among the women receiving ART for >1 month during
pregnancy, those who received a mono or a dual therapy
tended to have a higher risk of vertical transmission (3.1%)
compared to the women who received HAART (1.7%).
Due to the lack of power, this difference was not
significant, but it persisted after adjustment for other
obstetrical interventions, which indicates that it does not
only reflect a more systematic implementation of these
preventive interventions in the era of HAART.
In agreement with other studies, we showed that MTCT
was correlated with high maternal viral load and low CD4
count at delivery [5, 16]. In our cohort, the rate of
transmission was similar in elective cesarean section and
in vaginal delivery without episiotomy (6% and 5%,
respectively). Current guidelines no longer propose cesar-
ean section in mothers with undetectable viral load [9].
Several studies have suggested that the use of HAART
during pregnancy was associated with the increased risk of
preterm birth [4, 7, 14], although others could not confirm
this observation [15]. We found that HAART administered
for a short duration was associated with a higher risk of
preterm birth, which could either reflect the lower oppor-
tunity of women who deliver preterm in receiving treat-
ment, or represent an acute side-effect of HAART in a
subsample of women. Among the women treated for longer
periods, the differences between premature delivery be-
tween the mother receiving HAART and the mother
receiving mono or dual therapy was not significant, and
this might possibly be due to lack of the power due to the
small sample size. Obviously, there are other maternal
factors known to be associated with preterm delivery,
including ethnicity, socio-economic factors, illicit drug
use, poor quality of the obstetrical follow up, or poor
clinical status of the mother. In our cohort, most women
were of African origin and living in poor socio-economic
situations. The rate of premature birth in this population in
Brussels is known to be higher than in the general
population (9.7% vs. 7.4%) [8].
In conclusion, HAART given during pregnancy, together
with other preventive measures, allows us to dramatically
decrease the MTCT of HIV. However, transmission still
occurs at a high rate in the subgroup of women who miss
the opportunity to benefit from these interventions because
of a late diagnosis of HIV infection or poor antenatal care.
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